- Technology and Data
- Front End Sales and Marketing
- Allergy
- HIV
- Women's Health
- Migraine
- Compounding
- Continuous Glucose Monitoring
- Mental Health Awareness
- Veterinary Pharmacy
- CBD
- Infectious Disease
- Eye Health
- Digestive Health
- Biosimilars
- Influenza
- Shingles
- COPD Management
- Pediatrics
- Generics
- Pain Management
- COVID-19
- Immunization
- Oncology
- Anticoagulants
- Autoimmune Diseases
- Dermatology
- Diabetes
- Respiratory
- Heart Health
- Cardiovascular Clinical Consult
URAC set to beta test PBM accreditation measures
URAC has secured more than 10 organizations as beta-test sites for its accreditation standards for pharmacy benefit managers.
URAC has secured more than 10 organizations as beta-test sites for its accreditation standards for pharmacy benefit managers. The beta-test phase marks the largest group the organization has ever fielded for testing the new standards. Final standards for the commercially insured market are expected to be approved and issued this summer, but there are also indications that purchasers will expect industry leaders to step up immediately and seek the new accreditation status, according to URAC. Employers are already circulating RFIs for next year that ask PBM organizations whether they will be seeking URAC PBM accreditation. "This accreditation is greatly anticipated because of the need for all parties to better understand the practices of pharmacy benefit management organizations and to clearly recognize quality," said John DuMoulin, URAC VP of government relations and product development.
To see more Hot off the Press news articles, click here.
To go to the Drug Topics homepage, click here.
Antiseizure Medications Linked to Serious Potential Reaction, FDA Warns
November 30th 2023Levetiracetam and clobazam can cause Drug Reaction with Eosinophilia and Systemic Symptoms, which can start as a rash but progress quickly, potentially resulting in injury to internal organs, hospitalization, and death.
Examining Barriers to Care in Diabetic Retinopathy Screening
November 30th 2023Prior research has shown the association between various socioeconomic variables and lower adherence to diabetic retinopathy screening, but few have elaborated on the patient perspective to understand the reason behind this association.
